• Trade
  • Exchange
  • Buy
  • Trade
  • Exchange
  • Buy
Countdown to Ethereum Shanghai Hard Fork
What does that mean?
Total marketcap
Total volume
BTC 44.60%     ETH 17.64%
  • Trade
  • Exchange
  • Buy

AstraZeneca PLC AZNCF Stock

136.7 USD {{ price }} 2.182687% {{change_pct}}%
Other OTC
Market Cap
211.86B USD
LOW - HIGH [24H]
133.44 - 137.85 USD
5.34K USD
{{ volume }}
P/E Ratio
Earnings per share
2.16 USD

AstraZeneca PLC Price Chart

AstraZeneca PLC AZNCF Financial and Trading Overview

AstraZeneca PLC stock price 136.7 USD
Previous Close 133.78 USD
Open 137.85 USD
Bid 0 USD x 0
Ask 0 USD x 0
Day's Range 133.44 - 137.85 USD
52 Week Range 104.5 - 144.5 USD
Volume 5.34K USD
Avg. Volume 1.98K USD
Market Cap 212.47B USD
Beta (5Y Monthly) 0.173694
PE Ratio (TTM) 64.1784
EPS (TTM) 2.16 USD
Forward Dividend & Yield 2.83 (2.13%)
Ex-Dividend Date February 23, 2023
1y Target Est N/A

AZNCF Valuation Measures

Enterprise Value 232.24B USD
Trailing P/E 64.1784
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 4.79068
Price/Book (mrq) 5.720144
Enterprise Value/Revenue 5.237
Enterprise Value/EBITDA 16.714

Trading Information

AstraZeneca PLC Stock Price History

Beta (5Y Monthly) 0.173694
52-Week Change 2.45%
S&P500 52-Week Change -13.21%
52 Week High 144.5 USD
52 Week Low 104.5 USD
50-Day Moving Average 133.2 USD
200-Day Moving Average 127.35 USD

AZNCF Share Statistics

Avg. Volume (3 month) 1.98K USD
Avg. Daily Volume (10-Days) 3.29K USD
Shares Outstanding 1.55B
Float 1.54B
Short Ratio N/A
% Held by Insiders 0.22%
% Held by Institutions 47.73%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 2.9
Trailing Annual Dividend Yield 2.16%
5 Year Average Dividend Yield 284.00%
Payout Ratio 1.3428
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) December 31, 2022
Next Fiscal Year End December 31, 2023


Profit Margin 7.41%
Operating Margin (ttm) 20.20%
Gross Margin 80.56%
EBITDA Margin 31.33%

Management Effectiveness

Return on Assets (ttm) 5.55%
Return on Equity (ttm) 8.62%

Income Statement

Revenue (ttm) 44.35B USD
Revenue Per Share (ttm) 28.65 USD
Quarterly Revenue Growth (yoy) -6.70%
Gross Profit (ttm) 35.73B USD
Net Income Avi to Common (ttm) 3.29B USD
Diluted EPS (ttm) 2.13
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 6.24B USD
Total Cash Per Share (mrq) 4.03 USD
Total Debt (mrq) 31.14B USD
Total Debt/Equity (mrq) 84.02 USD
Current Ratio (mrq) 0.859
Book Value Per Share (mrq) 23.898

Cash Flow Statement

Operating Cash Flow (ttm) 9.81B USD
Levered Free Cash Flow (ttm) 12.36B USD

Profile of AstraZeneca PLC

Country United States
State N/A
City Cambridge
Address 1 Francis Crick Avenue
Phone 44 20 3749 5000
Website https://www.astrazeneca.com
Industry Drug Manufacturers-General
Sector(s) Healthcare
Full Time Employees 83500

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Q&A For AstraZeneca PLC Stock

What is a current AZNCF stock price?

AstraZeneca PLC AZNCF stock price today per share is 136.7 USD.

How to purchase AstraZeneca PLC stock?

You can buy AZNCF shares on the Other OTC exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for AstraZeneca PLC?

The stock symbol or ticker of AstraZeneca PLC is AZNCF.

Which industry does the AstraZeneca PLC company belong to?

The AstraZeneca PLC industry is Drug Manufacturers-General.

How many shares does AstraZeneca PLC have in circulation?

The max supply of AstraZeneca PLC shares is 1.55B.

What is AstraZeneca PLC Price to Earnings Ratio (PE Ratio)?

AstraZeneca PLC PE Ratio is 63.28703300 now.

What was AstraZeneca PLC earnings per share over the trailing 12 months (TTM)?

AstraZeneca PLC EPS is 2.16 USD over the trailing 12 months.

Which sector does the AstraZeneca PLC company belong to?

The AstraZeneca PLC sector is Healthcare.